中国药物经济学2024，Vol.19Issue(5)：30-35,41,7.DOI:10.12010/j.issn.1673-5846.2024.05.004
阿托西班与利托君治疗孕妇先兆早产的临床疗效与经济学评价
Clinical Efficacy and Economic Evaluation of Atosiban and Ritodrine in the Treatment of Pregnant Women with Threatened Preterm Birth
摘要
Abstract
Objective To evaluate the clinical efficacy and economics of Atosiban and Ritodrine in the treatment of threatened preterm birth.Methods A total of 66 pregnant women with threatened preterm delivery aged 17～42 years and between 24～33 weeks of gestation were included.23 and 43 pregnant women were treated with Atosiban or Ritodrine,respectively,to evaluate the effectiveness of the two groups.Two sets of direct medical cost data were collected from the perspective of medical institutions.Based on the 2022 RMB currency value,the cost data were discounted at a 5%discount rate to calculate the average cost and the difference between groups.The economy was evaluated according to the minimum cost analysis method,and the robustness of the research results was evaluated by sensitivity analysis.Results There were no significant differences in the success rate of pregnancy preservation,delivery rate within 48 h after hospitalization,delivery rate 48 h to 7 d after hospitalization and extended gestation time between the two groups(P＞0.05).There were no significant differences in gestational age,body weight,Apgar score(1 min vs.5 min),length of hospitalization,length of stay in neonatal intensive care unit(NICU),duration of continuous positive airway pressure(CPAP),incidence of brain injury,septicemia and retinopathy between the two groups(P＞0.05).The results of minimum cost analysis showed that the average hospitalization cost of Atosiban group was 23 588.5 yuan higher than that of Ritodrine group,indicating that Ritodrine had more economic advantages.Sensitivity analysis results showed that with the discount rate floating up and down by 8%,or when the patients were included in the stratized statistics according to whether they reached 30 weeks of pregnancy,the family hospitalization costs of Atosiban group were higher than those of Ritodrine group,and the evaluation results were unchanged.Conclusion The cost of Ritodrine is lower than that of Atosiban in the treatment of threatened preterm birth,and the efficacy is similar.关键词
先兆早产/阿托西班/利托君/最小成本分析法/宫缩抑制剂Key words
Threatened preterm birth/Atosiban/Ritodrine/Cost-minimization analysis/Uterine contraction inhibitors分类
医药卫生引用本文复制引用
赵冰封,陈冉,陈红波,孙晓静,许曼,夏涛,黄学桂..阿托西班与利托君治疗孕妇先兆早产的临床疗效与经济学评价[J].中国药物经济学,2024,19(5):30-35,41,7.基金项目
安徽省妇幼保健协会科研项目(2020FY12) （2020FY12）
